Related Experiment Video
Updated: Sep 26, 2025
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
16.0K
Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK
Hannah M Knochelmann1,2, Michael Brandon Ware2, Aditya Rali3
1Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, SC, United States.
Frontiers in Oncology
|April 18, 2022
Summary
BRAF/MEK inhibitors can cause delayed autoimmune-like reactions in melanoma patients. A type-17 cytokine signature was observed during severe toxicities, suggesting a role in pathogenesis.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Autoimmune toxicities are common with cancer immunotherapies but poorly understood with BRAF/MEK inhibitors.
- Emerging data link autoimmune effects to superior treatment responses, yet mechanisms remain unclear.
- This study investigates immune-related toxicity in a melanoma patient treated with BRAF/MEK inhibitors.
Observation:
- A 59-year-old male with metastatic melanoma developed severe, sudden-onset autoimmune-like toxicities after 18 months of BRAF/MEK inhibitor therapy.
- Symptoms included panuveitis, cytopenias, joint pain, rash, hypercalcemia, and interstitial nephritis, leading to treatment cessation.
- Immunological analysis revealed a peripheral type-17 cytokine signature (elevated IL-23, IL-6, IL-10, IL-17A/F, IL-1β, IL-21).
Findings:
- A novel delayed autoimmune-like reaction to BRAF/MEK inhibition was observed.
- The findings suggest a potential role for T-helper/T-cytotoxic 17 (Th/Tc17) activation in the pathogenesis of these toxicities.
- A distinct peripheral type-17 cytokine signature correlated with symptom severity.
Implications:
- Highlights a previously unrecognized delayed autoimmune-like reaction to BRAF/MEK inhibitors.
- Identifies a potential immunological mechanism involving Th/Tc17 pathways in BRAF/MEK inhibitor-induced toxicities.
- Warrants further clinical and immunological investigation into these delayed adverse events and their underlying mechanisms.
